Torbjørn Breivik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Torbjørn Breivik has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Per Kristian Opstad
Norwegian Defence Research Establishment, Division for Protection, Kjeller, Norway
8 shared publicationsP. Gjermo
Faculty of Dentistry Department of Periodontology University of Oslo Oslo Norway
7 shared publicationsFrode Fonnum
Norwegian Defence Research Establishment, Division of Protection, Kjeller, Norway
6 shared publicationsPer Gjermo
Department of Periodontology, Faculty of Dentistry, University of Oslo, Norway
6 shared publicationsP. K. Opstad
Division for Protection, Norwegian Defence Research Establishment, Kjeller, Norway
5 shared publicationsYngvar Gundersen
Norwegian Defence Research Establishment, Division for Protection, Kjeller, Norway
5 shared publications
Latest Publications
- Open Access
- 30 January 2015
- Published by Bentham Science Publishers Ltd. in The Open Dentistry Journal
- Vol. 9 (1) , 65-78
Maternal Deprivation of Lewis Rat Pups Increases the Severity of Experi-mental Periodontitis in Adulthood
Maternal Deprivation of Lewis Rat Pups Increases the Severity of Experi-mental Periodontitis in Adulthood
- 30 January 2015
- Published by Bentham Science Publishers Ltd. in The Open Dentistry Journal
- Vol. 9 (1) , 65-78
Open AccessMaternal Deprivation of Lewis Rat Pups Increases the Severity of Experi-mental Periodontitis in Adulthood
Maternal Deprivation of Lewis Rat Pups Increases the Severity of Experi-mental Periodontitis in Adulthood
- 16 April 2013
- Published by Wiley in Journal of Periodontal Research
- Vol. 49 (1) , 36-44
Chronic treatment with the glucocorticoid receptor antagonist RU486 inhibits diabetes‐induced enhancement of experimental periodontitis
Background and Objective: Chronic hypothalamic–pituitary–adrenal (HPA) axis hyperactivity and excessive glucocorticoid hormone release have been associated with diabetes, altered immune responses and increased susceptibility to periodontitis. In the present study we tested the impact of streptozotocin (STZ)‐induced diabetes on ligature‐induced periodontitis and the effect of subsequent treatment with the glucocorticoid receptor (GR) antagonist, RU486.Material and Methods: A single dose of STZ [45 mg/kg, intraperitoneally (i.p.)] or vehicle was given 10 d before induction of ligature‐induced periodontitis and implantation subcutaneously of a drug pellet containing the GR antagonist, RU486, or a placebo pellet. Periodontitis was assessed when the ligatures had been in place for 21 d. Two hours before decapitation all rats received gram‐negative bacterial lipopolysaccharide (LPS) (150 μg/kg, i.p.) to induce a robust immune and stress response.Results: Compared with control rats, STZ‐treated rats developed significantly more periodontal bone loss, and RU486 treatment of STZ ‐treated rats significantly inhibited this effect. STZ‐treated rats also showed significantly higher levels of the HPA axis‐derived hormone, corticosterone, as well as of the proinflammatory cytokine, tumor necrosis factor‐alpha (TNF‐α), but lower levels of the anti‐inflammatory cytokines interleukin‐10 (IL‐10) and transforming growth factor‐1beta (TGF‐1β) after LPS stimulation. GR blockade had no statistically significant effects on these measurements in diabetic rats, but tended to enhance the levels of TNF‐α and TGF‐1β, and reduce the levels of IL‐10 and blood glucose.Conclusion: In diabetic subjects, excessive GR activation as a result of chronic high levels of glucocorticoid hormones may alter immune‐system responses in a manner that may increase the susceptibility to periodontitis.
- 16 April 2013
- Published by Wiley in Journal of Periodontal Research
- Vol. 49 (1) , 36-44
Chronic treatment with the glucocorticoid receptor antagonist RU486 inhibits diabetes‐induced enhancement of experimental periodontitis
Background and Objective: Chronic hypothalamic–pituitary–adrenal (HPA) axis hyperactivity and excessive glucocorticoid hormone release have been associated with diabetes, altered immune responses and increased susceptibility to periodontitis. In the present study we tested the impact of streptozotocin (STZ)‐induced diabetes on ligature‐induced periodontitis and the effect of subsequent treatment with the glucocorticoid receptor (GR) antagonist, RU486.Material and Methods: A single dose of STZ [45 mg/kg, intraperitoneally (i.p.)] or vehicle was given 10 d before induction of ligature‐induced periodontitis and implantation subcutaneously of a drug pellet containing the GR antagonist, RU486, or a placebo pellet. Periodontitis was assessed when the ligatures had been in place for 21 d. Two hours before decapitation all rats received gram‐negative bacterial lipopolysaccharide (LPS) (150 μg/kg, i.p.) to induce a robust immune and stress response.Results: Compared with control rats, STZ‐treated rats developed significantly more periodontal bone loss, and RU486 treatment of STZ ‐treated rats significantly inhibited this effect. STZ‐treated rats also showed significantly higher levels of the HPA axis‐derived hormone, corticosterone, as well as of the proinflammatory cytokine, tumor necrosis factor‐alpha (TNF‐α), but lower levels of the anti‐inflammatory cytokines interleukin‐10 (IL‐10) and transforming growth factor‐1beta (TGF‐1β) after LPS stimulation. GR blockade had no statistically significant effects on these measurements in diabetic rats, but tended to enhance the levels of TNF‐α and TGF‐1β, and reduce the levels of IL‐10 and blood glucose.Conclusion: In diabetic subjects, excessive GR activation as a result of chronic high levels of glucocorticoid hormones may alter immune‐system responses in a manner that may increase the susceptibility to periodontitis.
- 3 July 2011
- Published by Wiley in Journal of Periodontal Research
- Vol. 46 (6) , 643-647
Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats
Breivik T, Gundersen Y, Gjermo P, Taylor SM, Woodruff TM, Opstad PK. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. J Periodont Res 2011; 46: 643–647. © 2011 John Wiley & Sons A/SBackground and Objective: The complement activation product 5a (C5a) is a potent mediator of the innate immune response to infection, and may thus also importantly determine the development of periodontitis. The present study was designed to explore the effect of several novel, potent and orally active C5a receptor (CD88) antagonists (C5aRAs) on the development of ligature‐induced periodontitis in an animal model.Material and Methods: Three different cyclic peptide C5aRAs, termed PMX205, PMX218 and PMX273, were investigated. Four groups of Wistar rats (n = 10 in each group) were used. Starting 3 d before induction of experimental periodontitis, rats either received one of the C5aRas (1–2 mg/kg) in the drinking water or received drinking water only. Periodontitis was assessed when the ligatures had been in place for 14 d.Results: Compared with control rats, PMX205‐ and PMX218‐treated rats had significantly reduced periodontal bone loss.Conclusion: The findings suggest that complement activation, and particularly C5a generation, may play a significant role in the development and progression of periodontitis. Blockade of the major C5a receptor, CD88, with specific inhibitors such as PMX205, may offer novel treatment options for periodontitis.
- 3 July 2011
- Published by Wiley in Journal of Periodontal Research
- Vol. 46 (6) , 643-647
Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats
Breivik T, Gundersen Y, Gjermo P, Taylor SM, Woodruff TM, Opstad PK. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. J Periodont Res 2011; 46: 643–647. © 2011 John Wiley & Sons A/SBackground and Objective: The complement activation product 5a (C5a) is a potent mediator of the innate immune response to infection, and may thus also importantly determine the development of periodontitis. The present study was designed to explore the effect of several novel, potent and orally active C5a receptor (CD88) antagonists (C5aRAs) on the development of ligature‐induced periodontitis in an animal model.Material and Methods: Three different cyclic peptide C5aRAs, termed PMX205, PMX218 and PMX273, were investigated. Four groups of Wistar rats (n = 10 in each group) were used. Starting 3 d before induction of experimental periodontitis, rats either received one of the C5aRas (1–2 mg/kg) in the drinking water or received drinking water only. Periodontitis was assessed when the ligatures had been in place for 14 d.Results: Compared with control rats, PMX205‐ and PMX218‐treated rats had significantly reduced periodontal bone loss.Conclusion: The findings suggest that complement activation, and particularly C5a generation, may play a significant role in the development and progression of periodontitis. Blockade of the major C5a receptor, CD88, with specific inhibitors such as PMX205, may offer novel treatment options for periodontitis.
- Open Access
- 6 January 2011
- Published by Bentham Science Publishers Ltd. in The Open Dentistry Journal
- Vol. 05 (1) , 1-6
Systemic Chemical Desensitization of Peptidergic Sensory Neurons with Resiniferatoxin Inhibits Experimental Periodontitis
Background and objective: The immune system is an important player in the pathophysiology of periodontitis. The brain controls immune responses via neural and hormonal pathways, and brain-neuro-endocrine dysregulation may be a central determinant for pathogenesis. Our current knowledge also emphasizes the central role of sensory nerves. In line with this, we wanted to investigate how desensitization of peptidergic sensory neurons influences the progression of ligature-induced periodontitis, and, furthermore, how selected cytokine and stress hormone responses to Gram-negative bacterial lipopolysaccharide (LPS) stimulation are affected. Material and methods: Resiniferatoxin (RTX; 50 μg/kg) or vehicle was injected subcutaneously on days 1, 2, and 3 in stress high responding and periodontitis-susceptible Fischer 344 rats. Periodontitis was induced 2 days thereafter. Progression of the disease was assessed after the ligatures had been in place for 20 days. Two h before decapitation all rats received LPS (150 μg/kg i.p.) to induce a robust immune and stress response. Results: Desensitization with RTX significantly reduced bone loss as measured by digital X-rays. LPS provoked a significantly higher increase in serum levels of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α, but lower serum levels of the anti-inflammatory cytokine interleukin (IL)-10 and the stress hormone corticosterone. Conclusions: In this model RTX-induced chemical desensitization of sensory peptidergic neurons attenuated ligature-induced periodontitis and promoted a shift towards stronger pro-inflammatory cytokine and weaker stress hormone responses to LPS. The results may partly be explained by the attenuated transmission of immuno-inflammatory signals to the brain. In turn, this may weaken the anti-inflammatory brain-derived pathways.
- 6 January 2011
- Published by Bentham Science Publishers Ltd. in The Open Dentistry Journal
- Vol. 05 (1) , 1-6
Open AccessSystemic Chemical Desensitization of Peptidergic Sensory Neurons with Resiniferatoxin Inhibits Experimental Periodontitis
Background and objective: The immune system is an important player in the pathophysiology of periodontitis. The brain controls immune responses via neural and hormonal pathways, and brain-neuro-endocrine dysregulation may be a central determinant for pathogenesis. Our current knowledge also emphasizes the central role of sensory nerves. In line with this, we wanted to investigate how desensitization of peptidergic sensory neurons influences the progression of ligature-induced periodontitis, and, furthermore, how selected cytokine and stress hormone responses to Gram-negative bacterial lipopolysaccharide (LPS) stimulation are affected. Material and methods: Resiniferatoxin (RTX; 50 μg/kg) or vehicle was injected subcutaneously on days 1, 2, and 3 in stress high responding and periodontitis-susceptible Fischer 344 rats. Periodontitis was induced 2 days thereafter. Progression of the disease was assessed after the ligatures had been in place for 20 days. Two h before decapitation all rats received LPS (150 μg/kg i.p.) to induce a robust immune and stress response. Results: Desensitization with RTX significantly reduced bone loss as measured by digital X-rays. LPS provoked a significantly higher increase in serum levels of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α, but lower serum levels of the anti-inflammatory cytokine interleukin (IL)-10 and the stress hormone corticosterone. Conclusions: In this model RTX-induced chemical desensitization of sensory peptidergic neurons attenuated ligature-induced periodontitis and promoted a shift towards stronger pro-inflammatory cytokine and weaker stress hormone responses to LPS. The results may partly be explained by the attenuated transmission of immuno-inflammatory signals to the brain. In turn, this may weaken the anti-inflammatory brain-derived pathways.
- 27 April 2009
- Published by Wiley in Journal of Periodontal Research
- Vol. 44 (3) , 297-304
Nicotinic acetylcholine receptor activation mediates nicotine‐induced enhancement of experimental periodontitis
Smokers have an increased risk of developing periodontitis as well as showing more rapid progression and resistance to treatment of the disease, but the biological mechanisms are poorly understood. This study was designed to investigate putative biological mechanisms by which nicotine may enhance the susceptibility and thus the course of periodontitis in an animal model. Ligature-induced periodontitis was applied in periodontitis-susceptible Fischer 344 rats. The animals were either given daily intraperitoneal injections of the nicotinic acetylcholine receptor antagonist mecamylamine (1 mg/kg) 45 min before subcutaneous injections in the neck skin of nicotine (0.8 mg/kg), or treated with the same amount of saline intraperitoneally and nicotine subcutaneously, or treated with mecamylamine and saline. Control animals received intraperitoneal and subcutaneous injections of saline only. Periodontal bone loss was assessed when the ligatures had been in place for 3 wk. Two hours before decapitation, all rats received lipopolysaccharide (LPS; 100 microg/kg, intraperitoneally) to induce a robust immune and stress response. Compared with saline/saline-treated control animals, saline/nicotine-treated rats developed significantly more periodontal bone loss, and LPS provoked a significantly smaller increase in circulating levels of the cytokines tumour necrosis factor-alpha, transforming growth factor-1beta and interleukin-10. Mecamylamine pretreatment of nicotine-treated rats abrogated the increased periodontal bone loss and the LPS-induced decrease in tumour necrosis factor-alpha, but had no significant effects on the levels of transforming growth factor-1beta and interleukin-10, or the stress hormone corticosterone. The results indicate that nicotine enhances the susceptibility to periodontitis via nicotinic acetylcholine receptors, which may act by suppressing protective immune responses through the cholinergic anti-inflammatory pathway.
- 27 April 2009
- Published by Wiley in Journal of Periodontal Research
- Vol. 44 (3) , 297-304
Nicotinic acetylcholine receptor activation mediates nicotine‐induced enhancement of experimental periodontitis
Smokers have an increased risk of developing periodontitis as well as showing more rapid progression and resistance to treatment of the disease, but the biological mechanisms are poorly understood. This study was designed to investigate putative biological mechanisms by which nicotine may enhance the susceptibility and thus the course of periodontitis in an animal model. Ligature-induced periodontitis was applied in periodontitis-susceptible Fischer 344 rats. The animals were either given daily intraperitoneal injections of the nicotinic acetylcholine receptor antagonist mecamylamine (1 mg/kg) 45 min before subcutaneous injections in the neck skin of nicotine (0.8 mg/kg), or treated with the same amount of saline intraperitoneally and nicotine subcutaneously, or treated with mecamylamine and saline. Control animals received intraperitoneal and subcutaneous injections of saline only. Periodontal bone loss was assessed when the ligatures had been in place for 3 wk. Two hours before decapitation, all rats received lipopolysaccharide (LPS; 100 microg/kg, intraperitoneally) to induce a robust immune and stress response. Compared with saline/saline-treated control animals, saline/nicotine-treated rats developed significantly more periodontal bone loss, and LPS provoked a significantly smaller increase in circulating levels of the cytokines tumour necrosis factor-alpha, transforming growth factor-1beta and interleukin-10. Mecamylamine pretreatment of nicotine-treated rats abrogated the increased periodontal bone loss and the LPS-induced decrease in tumour necrosis factor-alpha, but had no significant effects on the levels of transforming growth factor-1beta and interleukin-10, or the stress hormone corticosterone. The results indicate that nicotine enhances the susceptibility to periodontitis via nicotinic acetylcholine receptors, which may act by suppressing protective immune responses through the cholinergic anti-inflammatory pathway.
- 1 February 2009
- Published by Wiley in Journal of Periodontal Research
- Vol. 44 (1) , 110-116
Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis
Smokers have an increased risk of developing periodontitis as well as showing more rapid progression and resistance to treatment of the disease, but the biological mechanisms are poorly understood. Our objective was to investigate putative biological mechanisms by which nicotine may enhance the susceptibility and thus the course of periodontitis in an animal model. Ligature-induced periodontitis was applied in periodontitis-susceptible Fischer 344 rats. The animals were given daily intraperiotonal (i.p.) injections of the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (1 mg/kg) 45 min before subcutaneous (s.c.) injections in the neck skin with nicotine (0.8 mg/kg), or treated with the same amount of saline i.p. and nicotine s.c., or with mecamylamine and saline. Control rats received i.p. and s.c. injections of saline only. Periodontal bone loss was assessed when the ligatures had been in place for 3 weeks. Two hours before decapitation, all rats received lipopolysaccharide (LPS; 100 microg/kg, i.p.) to induce a robust immune and stress response. Compared with saline/saline-treated control rats, saline/nicotine-treated rats developed significantly more periodontal bone loss, and LPS provoked a significantly smaller increase in circulating levels of the cytokines tumour necrosis factor alpha (TNF-alpha), transforming growth factor 1beta (TGF-1beta) and interleukin-10 (IL-10). Mecamylamine pretreatment of nicotine-treated rats abrogated the increased periodontal bone loss and the LPS-induced TNF-alpha decrease, but had no significant effects on the levels of TGF-1beta and IL-10, or the stress hormone corticosterone. The results indicate that nicotine enhances susceptibility to periodontitis via nAChRs, which may act via suppressing protective immune responses through the cholinergic anti-inflammatory pathway.
- 1 February 2009
- Published by Wiley in Journal of Periodontal Research
- Vol. 44 (1) , 110-116
Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis
Smokers have an increased risk of developing periodontitis as well as showing more rapid progression and resistance to treatment of the disease, but the biological mechanisms are poorly understood. Our objective was to investigate putative biological mechanisms by which nicotine may enhance the susceptibility and thus the course of periodontitis in an animal model. Ligature-induced periodontitis was applied in periodontitis-susceptible Fischer 344 rats. The animals were given daily intraperiotonal (i.p.) injections of the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (1 mg/kg) 45 min before subcutaneous (s.c.) injections in the neck skin with nicotine (0.8 mg/kg), or treated with the same amount of saline i.p. and nicotine s.c., or with mecamylamine and saline. Control rats received i.p. and s.c. injections of saline only. Periodontal bone loss was assessed when the ligatures had been in place for 3 weeks. Two hours before decapitation, all rats received lipopolysaccharide (LPS; 100 microg/kg, i.p.) to induce a robust immune and stress response. Compared with saline/saline-treated control rats, saline/nicotine-treated rats developed significantly more periodontal bone loss, and LPS provoked a significantly smaller increase in circulating levels of the cytokines tumour necrosis factor alpha (TNF-alpha), transforming growth factor 1beta (TGF-1beta) and interleukin-10 (IL-10). Mecamylamine pretreatment of nicotine-treated rats abrogated the increased periodontal bone loss and the LPS-induced TNF-alpha decrease, but had no significant effects on the levels of TGF-1beta and IL-10, or the stress hormone corticosterone. The results indicate that nicotine enhances susceptibility to periodontitis via nAChRs, which may act via suppressing protective immune responses through the cholinergic anti-inflammatory pathway.
- 1 June 2006
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 33 (7) , 469-477
Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti‐depressant tianeptine
Objective:To test the hypothesis that the olfactory bulbectomy model of depression in rats could influence susceptibility to ligature‐induced periodontitis, and that chronic treatment with the anti‐depressant drug tianeptine could attenuate this effect.Material and Methods:Tianeptine was given twice daily (10 mg/kg, i.p.) during the entire experiment, starting 29 days before induction of olfactory bulbectomy and periodontitis. Olfactory bulbectomized (OB) rats and sham‐operated rats were given saline in a similar manner. Periodontal disease was assessed when the ligatures had been in place for 21 days. Two hours before decapitation, rats were injected with lipopolysaccharide (LPS;100 μg/kg, i.p.) to induce a robust immune and stress response.Results:Compared with sham‐operated controls, OB rats developed significantly more periodontal bone loss, exhibited characteristic behavioural responses in a novel open field test, and showed a decreased expression of glucocorticoid receptors (GRs) in the hippocampus. LPS provoked a significantly larger increase in circulating levels of the stress hormone corticosterone and the cytokine transformation growth factor (TGF)‐1β but smaller tumour necrosis factor (TNF)‐α levels. Tianeptine treatment of OB rats significantly inhibited peridodontal bone loss, normalized behavioural responses, enhanced TGF‐1β levels, and abolished TNF‐α decrease, but did not attenuate the increased corticosterone response and the decreased hippocampal GR expression.Conclusions:These experimental results are consistent with an emerging literature showing that life stress, anxiety, depression, pathological grief, and poor coping behaviour may dysregulate regulatory mechanisms within the brain involved in immune regulation, and thereby alter immune responses and influence the susceptibility/resistance to inflammatory disorders.
- 1 June 2006
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 33 (7) , 469-477
Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti‐depressant tianeptine
Objective:To test the hypothesis that the olfactory bulbectomy model of depression in rats could influence susceptibility to ligature‐induced periodontitis, and that chronic treatment with the anti‐depressant drug tianeptine could attenuate this effect.Material and Methods:Tianeptine was given twice daily (10 mg/kg, i.p.) during the entire experiment, starting 29 days before induction of olfactory bulbectomy and periodontitis. Olfactory bulbectomized (OB) rats and sham‐operated rats were given saline in a similar manner. Periodontal disease was assessed when the ligatures had been in place for 21 days. Two hours before decapitation, rats were injected with lipopolysaccharide (LPS;100 μg/kg, i.p.) to induce a robust immune and stress response.Results:Compared with sham‐operated controls, OB rats developed significantly more periodontal bone loss, exhibited characteristic behavioural responses in a novel open field test, and showed a decreased expression of glucocorticoid receptors (GRs) in the hippocampus. LPS provoked a significantly larger increase in circulating levels of the stress hormone corticosterone and the cytokine transformation growth factor (TGF)‐1β but smaller tumour necrosis factor (TNF)‐α levels. Tianeptine treatment of OB rats significantly inhibited peridodontal bone loss, normalized behavioural responses, enhanced TGF‐1β levels, and abolished TNF‐α decrease, but did not attenuate the increased corticosterone response and the decreased hippocampal GR expression.Conclusions:These experimental results are consistent with an emerging literature showing that life stress, anxiety, depression, pathological grief, and poor coping behaviour may dysregulate regulatory mechanisms within the brain involved in immune regulation, and thereby alter immune responses and influence the susceptibility/resistance to inflammatory disorders.
- 21 November 2005
- Published by Wiley in Journal of Periodontal Research
- Vol. 41 (1) , 23-32
Neonatal dexamethasone and chronic tianeptine treatment inhibit ligature‐induced periodontitis in adult rats
Objective: The responsiveness of the hypothalamic–pituitary–adrenal (HPA) axis has been found to play a significant role for susceptibility and resistance to periodontal disease. In the present study we have investigated the effects of two different treatment strategies, which have been found to down‐regulate the HPA axis, on ligature‐induced periodontitis.Methods: In experiment 1, newborn rats were treated with the synthetic glucocorticoid hormone dexamethasone‐21‐phosphate, which permanently down‐regulates HPA axis responsiveness. In experiment 2, adult rats were treated with the novel antidepressant drug tianeptine, which opposes the action of stress. Periodontitis was inflicted upon all rats. Just before decapitation the animals received gram‐negative bacterial lipopolysaccharide (LPS) to induce a robust immune and HPA axis response.Results: Compared to the saline‐treated control rats, dexamethasone‐treated rats had significantly less periodontal bone loss (p < 0.01), reduced expression of glucocorticoid receptors in the hippocampus (p < 0.001), lower corticosterone (p = 0.01) and higher plasma levels of the cytokine tumor necrosis factor (TNF)‐α (p < 0.05) after LPS challenge. Also the tianeptine‐treated rats showed significantly reduced periodontal bone loss (p = 0.01), enhanced plasma levels of TNF‐α (p < 0.05), and transforming growth factor‐1β (p < 0.01), whereas no significant difference was found in corticosterone levels.Conclusion: An individual's responsiveness to danger signals, whether they are of immunological, chemical, or psychological origin, may be an important factor for explaining variability in susceptibility to periodontal disease. The results may provide new insight into the mechanisms of periodontal disease development, and open new vistas for disease prevention.
- 21 November 2005
- Published by Wiley in Journal of Periodontal Research
- Vol. 41 (1) , 23-32
Neonatal dexamethasone and chronic tianeptine treatment inhibit ligature‐induced periodontitis in adult rats
Objective: The responsiveness of the hypothalamic–pituitary–adrenal (HPA) axis has been found to play a significant role for susceptibility and resistance to periodontal disease. In the present study we have investigated the effects of two different treatment strategies, which have been found to down‐regulate the HPA axis, on ligature‐induced periodontitis.Methods: In experiment 1, newborn rats were treated with the synthetic glucocorticoid hormone dexamethasone‐21‐phosphate, which permanently down‐regulates HPA axis responsiveness. In experiment 2, adult rats were treated with the novel antidepressant drug tianeptine, which opposes the action of stress. Periodontitis was inflicted upon all rats. Just before decapitation the animals received gram‐negative bacterial lipopolysaccharide (LPS) to induce a robust immune and HPA axis response.Results: Compared to the saline‐treated control rats, dexamethasone‐treated rats had significantly less periodontal bone loss (p < 0.01), reduced expression of glucocorticoid receptors in the hippocampus (p < 0.001), lower corticosterone (p = 0.01) and higher plasma levels of the cytokine tumor necrosis factor (TNF)‐α (p < 0.05) after LPS challenge. Also the tianeptine‐treated rats showed significantly reduced periodontal bone loss (p = 0.01), enhanced plasma levels of TNF‐α (p < 0.05), and transforming growth factor‐1β (p < 0.01), whereas no significant difference was found in corticosterone levels.Conclusion: An individual's responsiveness to danger signals, whether they are of immunological, chemical, or psychological origin, may be an important factor for explaining variability in susceptibility to periodontal disease. The results may provide new insight into the mechanisms of periodontal disease development, and open new vistas for disease prevention.
- 20 June 2005
- Published by Wiley in Journal of Periodontal Research
- Vol. 40 (4) , 325-330
Chemical sympathectomy inhibits periodontal disease in Fischer 344 rats
Objective: The responsiveness of the sympathetic nervous system (SNS) and the hypothalamic–pituitary–adrenal (HPA) axis plays a major role in immune regulation and for the outcome of infections and inflammatory disorders. This study was designed to investigate whether chemical SNS denervation with the noradrenaline‐selective neurotoxic drug 6‐hydroxydopamine (6‐OHDA), which destroys peripheral noradrenaline terminals, would influence immune responses to Gram‐negative bacterial lipopolysaccharide (LPS) stimulation, and the progression of ligature‐induced periodontal disease in Fischer 344 rats.Material and methods: 6‐OHDA (40–60 µg/kg) or vehicle was injected intraperitoneally (i.p.) on days 1, 3 and 5, 10 days before application of the ligatures, and thereafter weekly in doses of 80 µg/kg. Periodontal disease was assessed when the ligatures had been in place for 49 days. At 24 and 2 h before decapitation, all rats received LPS (150 µg/kg i.p.) to induce a robust immune and HPA axis response.Results: The 6‐OHDA‐treated rats showed significantly reduced bone loss as measured by digital X‐rays (p < 0.01), and enhanced levels of the cytokines transforming growth factor‐β (p = 0.05) and interleukin‐6 (p = 0.05), as well as the HPA axis derived hormone corticosterone (p = 0.01), induced by LPS stimulation.Conclusions: 6‐OHDA‐induced chemical sympathectomy inhibits ligature‐induced periodontal disease in this model. This effect may be attributable to the well‐documented ability of the SNS to regulate immune system function primarily via the adrenergic neurotransmitter noradrenaline released at sympathetic nerve terminals. The enhanced HPA axis activation may be a compensatory response that reduces the T helper (Th)2 to Th1 skewing effect of treatment with 6‐OHDA.
- 20 June 2005
- Published by Wiley in Journal of Periodontal Research
- Vol. 40 (4) , 325-330
Chemical sympathectomy inhibits periodontal disease in Fischer 344 rats
Objective: The responsiveness of the sympathetic nervous system (SNS) and the hypothalamic–pituitary–adrenal (HPA) axis plays a major role in immune regulation and for the outcome of infections and inflammatory disorders. This study was designed to investigate whether chemical SNS denervation with the noradrenaline‐selective neurotoxic drug 6‐hydroxydopamine (6‐OHDA), which destroys peripheral noradrenaline terminals, would influence immune responses to Gram‐negative bacterial lipopolysaccharide (LPS) stimulation, and the progression of ligature‐induced periodontal disease in Fischer 344 rats.Material and methods: 6‐OHDA (40–60 µg/kg) or vehicle was injected intraperitoneally (i.p.) on days 1, 3 and 5, 10 days before application of the ligatures, and thereafter weekly in doses of 80 µg/kg. Periodontal disease was assessed when the ligatures had been in place for 49 days. At 24 and 2 h before decapitation, all rats received LPS (150 µg/kg i.p.) to induce a robust immune and HPA axis response.Results: The 6‐OHDA‐treated rats showed significantly reduced bone loss as measured by digital X‐rays (p < 0.01), and enhanced levels of the cytokines transforming growth factor‐β (p = 0.05) and interleukin‐6 (p = 0.05), as well as the HPA axis derived hormone corticosterone (p = 0.01), induced by LPS stimulation.Conclusions: 6‐OHDA‐induced chemical sympathectomy inhibits ligature‐induced periodontal disease in this model. This effect may be attributable to the well‐documented ability of the SNS to regulate immune system function primarily via the adrenergic neurotransmitter noradrenaline released at sympathetic nerve terminals. The enhanced HPA axis activation may be a compensatory response that reduces the T helper (Th)2 to Th1 skewing effect of treatment with 6‐OHDA.
- 29 March 2005
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 32 (4) , 347-352
Soluble β‐1,3/1,6‐glucan from yeast inhibits experimental periodontal disease in Wistar rats
Objective: We have investigated whether a purified immunomodulatory water soluble β‐1,3/1,6‐glucan isolated from the cell wall of Bakers yeast, Saccharomyces cerevisiae, would influence the progression of ligature‐induced periodontal disease, and to modulate accompanying cytokine and hypothalamic–pituitary–adrenal (HPA) axis responses to a lipopolysaccharide (LPS) challenge.Material and Methods: β‐1,3/1,6‐glucan (10 mg/kg/day) was given in the drinking water to Wistar rats during the entire experiment, starting 14 days before disease induction, while control rats were given tap water only. Periodontal disease was assessed when the ligatures had been in place for 35 days.Results: Orally administered soluble β‐1,3/1,6‐glucan significantly reduced periodontal bone loss as measured on digital X‐rays (p=0,026). Glucan‐treated rats also showed a significantly enhanced plasma level of the HPA axis‐driven hormone corticosterone (p=0.047), and of the cytokine transforming growth factor‐1β (p=0.032), as well as a tendency to enhanced IL‐10 (p=0.106), induced by intra‐peritoneally administered LPS.Conclusion: Soluble β‐1,3/1,6‐glucan administered by the oral route diminishes ligature‐induced periodontal bone loss in this model. This effect may be attributable to the well documented ability of β‐1,3/1,6‐glucan to stimulate macrophage phagocytosis and to skew the T helper (Th)1/Th2 balance towards Th1 and T regulatory responses. The HPA axis may play a significant role in β‐1,3/1,6‐glucan induced immune modulation.
- 29 March 2005
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 32 (4) , 347-352
Soluble β‐1,3/1,6‐glucan from yeast inhibits experimental periodontal disease in Wistar rats
Objective: We have investigated whether a purified immunomodulatory water soluble β‐1,3/1,6‐glucan isolated from the cell wall of Bakers yeast, Saccharomyces cerevisiae, would influence the progression of ligature‐induced periodontal disease, and to modulate accompanying cytokine and hypothalamic–pituitary–adrenal (HPA) axis responses to a lipopolysaccharide (LPS) challenge.Material and Methods: β‐1,3/1,6‐glucan (10 mg/kg/day) was given in the drinking water to Wistar rats during the entire experiment, starting 14 days before disease induction, while control rats were given tap water only. Periodontal disease was assessed when the ligatures had been in place for 35 days.Results: Orally administered soluble β‐1,3/1,6‐glucan significantly reduced periodontal bone loss as measured on digital X‐rays (p=0,026). Glucan‐treated rats also showed a significantly enhanced plasma level of the HPA axis‐driven hormone corticosterone (p=0.047), and of the cytokine transforming growth factor‐1β (p=0.032), as well as a tendency to enhanced IL‐10 (p=0.106), induced by intra‐peritoneally administered LPS.Conclusion: Soluble β‐1,3/1,6‐glucan administered by the oral route diminishes ligature‐induced periodontal bone loss in this model. This effect may be attributable to the well documented ability of β‐1,3/1,6‐glucan to stimulate macrophage phagocytosis and to skew the T helper (Th)1/Th2 balance towards Th1 and T regulatory responses. The HPA axis may play a significant role in β‐1,3/1,6‐glucan induced immune modulation.